These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 27863657)

  • 21. Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei.
    Fitzgerald K; Bergeron M; Willits C; Bowers S; Aubele DL; Goldbach E; Tonn G; Ness D; Olaharski A
    Toxicol Appl Pharmacol; 2013 May; 269(1):1-7. PubMed ID: 23466428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner.
    Hara S; Arawaka S; Sato H; Machiya Y; Cui C; Sasaki A; Koyama S; Kato T
    Mol Biol Cell; 2013 Jun; 24(11):1649-60, S1-3. PubMed ID: 23576548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polo-like kinase 2 modulates α-synuclein protein levels by regulating its mRNA production.
    Kofoed RH; Zheng J; Ferreira N; Lykke-Andersen S; Salvi M; Betzer C; Reimer L; Jensen TH; Fog K; Jensen PH
    Neurobiol Dis; 2017 Oct; 106():49-62. PubMed ID: 28648742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2.
    Wang S; Xu B; Liou LC; Ren Q; Huang S; Luo Y; Zhang Z; Witt SN
    Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16119-24. PubMed ID: 22988096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenuigenin attenuates α-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3.
    Zhou JX; Zhang HB; Huang Y; He Y; Zheng Y; Anderson JP; Gai WP; Liang ZG; Wang Y; Ren XM; Wang Q; Gong XL; Yang J; Wang X; Halliday G; Wang XM
    CNS Neurosci Ther; 2013 Sep; 19(9):688-94. PubMed ID: 23710708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Copper Dependent Modulation of α-Synuclein Phosphorylation in Differentiated SHSY5Y Neuroblastoma Cells.
    Greco M; Spinelli CC; De Riccardis L; Buccolieri A; Di Giulio S; Musarò D; Pagano C; Manno D; Maffia M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective effects of extract of Acanthopanax senticosus harms on SH-SY5Y cells overexpressing wild-type or A53T mutant α-synuclein.
    Li XZ; Zhang SN; Wang KX; Liu HY; Yang ZM; Liu SM; Lu F
    Phytomedicine; 2014 Apr; 21(5):704-11. PubMed ID: 24252343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen-related receptor gamma regulates dopaminergic neuronal phenotype by activating GSK3β/NFAT signaling in SH-SY5Y cells.
    Lim J; Choi HS; Choi HJ
    J Neurochem; 2015 May; 133(4):544-57. PubMed ID: 25727910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.
    Credle JJ; George JL; Wills J; Duka V; Shah K; Lee YC; Rodriguez O; Simkins T; Winter M; Moechars D; Steckler T; Goudreau J; Finkelstein DI; Sidhu A
    Cell Death Differ; 2015 May; 22(5):838-51. PubMed ID: 25394490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H; Kato T; Arawaka S
    Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.
    Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain.
    Aubele DL; Hom RK; Adler M; Galemmo RA; Bowers S; Truong AP; Pan H; Beroza P; Neitz RJ; Yao N; Lin M; Tonn G; Zhang H; Bova MP; Ren Z; Tam D; Ruslim L; Baker J; Diep L; Fitzgerald K; Hoffman J; Motter R; Fauss D; Tanaka P; Dappen M; Jagodzinski J; Chan W; Konradi AW; Latimer L; Zhu YL; Sham HL; Anderson JP; Bergeron M; Artis DR
    ChemMedChem; 2013 Aug; 8(8):1295-313. PubMed ID: 23794260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystal structure of the polo-box domain of polo-like kinase 2.
    Shan HM; Wang T; Quan JM
    Biochem Biophys Res Commun; 2015 Jan; 456(3):780-4. PubMed ID: 25511705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of the PLK2-dependent phosphopeptidome by quantitative proteomics [corrected].
    Franchin C; Cesaro L; Pinna LA; Arrigoni G; Salvi M
    PLoS One; 2014; 9(10):e111018. PubMed ID: 25338102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event.
    Kosten J; Binolfi A; Stuiver M; Verzini S; Theillet FX; Bekei B; van Rossum M; Selenko P
    ACS Chem Neurosci; 2014 Dec; 5(12):1203-8. PubMed ID: 25320964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells.
    Perfeito R; Lázaro DF; Outeiro TF; Rego AC
    Mol Cell Neurosci; 2014 Sep; 62():51-9. PubMed ID: 25109238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins.
    Slone SR; Lavalley N; McFerrin M; Wang B; Yacoubian TA
    Neurobiol Dis; 2015 Jul; 79():1-13. PubMed ID: 25862939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The novel mechanism of rotenone-induced α-synuclein phosphorylation via reduced protein phosphatase 2A activity.
    Wang Y; Liu J; Chen M; Du T; Duan C; Gao G; Yang H
    Int J Biochem Cell Biol; 2016 Jun; 75():34-44. PubMed ID: 27012437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.